Clinical Research Directory
Browse clinical research sites, groups, and studies.
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Sponsor: Odense University Hospital
Summary
Aim To test if proton therapy can improve survival compared to photon therapy in patients with locally advanced NSCLC who are not candidates for standard definitive chemo-radiotherapy. Hypothesis The trial hypothesis is that proton therapy is less toxic than photon therapy in fragile patients and that this difference will mitigate to a difference in overall survival. Design Multicentre, randomized phase II study 1:1 Sample size 182 patients (91 in each arm) Treatment Radiotherapy (inhomogeneous dose distribution) 50 Gy/ 24 fraction Endpoint Primary: Overall survival at 12 months Secondary: progression free survival, time to loco-regional and distant failure, pattern of failure, acute and late toxicity, quality of life, patient compliance.
Official title: HERAN2 Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC A Randomised Multicentre Phase II Feasibility Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
182
Start Date
2022-10-01
Completion Date
2029-09-30
Last Updated
2022-09-21
Healthy Volunteers
No
Interventions
Photon
50-66Gy/ 24 fractions, inhomogeneous dose distribution photon therapy
Proton
50-66Gy/ 24 fractions, inhomogeneous dose distribution proton therapy